Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Scientists Invent Capsule Technology to Treat Hemophilia

By Ryan Bushey | November 29, 2016

Engineers based at the University of Texas at Austin created a biodegradable oral delivery system for treating hemophilia B that could counteract some of the issues linked to treating this bleeding disorder.

Approximately 400,000 people all over the world are living with either hemophilia A or hemophilia B where they must use an arduous, expensive needle-based administration system in order to combat this condition, per the university’s announcement.

Access to these medications is limited in some parts of the world due to cost while patients must contend with multiple weekly injections to keep symptoms like excessive bleeding under control.  

This new system is a capsule comprised of micro and nanoparticles that administers a protein therapy called human factor IX (hFIX) for treating hemophilia B.

Test runs of the prototype demonstrated it could safely travel through the stomach to the small intestine where it begins to swell due to an increase in pH levels. The major intestinal enzyme then begins to degrade the capsule’s shell slowly releasing the drug over an unspecified period of time.

“Based on the current capabilities of this system, approximately two capsules would be equivalent to one injection,” said Sarena Horava, the lead study author and recent Ph.D., graduate of the University of Texas at Austin’s school engineering, in a statement. “However, we anticipate that we will make further improvements to the delivery capacity of the oral delivery system and therefore decrease the capsule amount.”

Ultimately, Horava and her colleagues feel this technology will benefit patients in developing countries the most.

“In many developing countries, the median life expectancy for hemophilia patients is 11 years due to the lack of access to treatment, but our new oral delivery of factor IX can now overcome these issues and improve the worldwide use of this therapy,” added Horava.

The team plans on conducting more tests to verify the system’s capabilities before initiating clinical trials.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE